School of Medicine


Showing 1-10 of 19 Results

  • Kenneth Mahaffey

    Kenneth Mahaffey

    Professor of Medicine (Cardiovascular Medicine) at the Stanford University Medical Center

    Bio Clinical Focus: Cardiovascular Medicine

    Research Focus:

    My primary research interest is the design and conduct of multicenter clinical trials and analyses of important clinical cardiac issues using large patient databases. My research focuses on novel anticoagulation agents for the treatment of acute coronary syndromes and atrial fibrillation, the study of agents targeted to protect the myocardium during reperfusion therapy for acute myocardial infarction, and the evaluation of cardiovascular safety of diabetic therapies. I am also interested in the methodology of clinical trials. Current research activities include standardization of the definition of myocardial infarction used in clinical trials, the adjudication of suspected clinical endpoint events by Clinical Event Committees (CEC), and the efficient operational conduct of large multinational clinical trials.

    Administrative Focus: Vice Chair of Clinical Research in the Department of Medicine and Member of the Stanford IRB

    Professional Training:

    1985 Stanford University, BS Chemistry
    1989 University of Washington, MD
    1993 University of Arizona, Internship/Residency/Chief Residency
    1996 Duke University, Fellowship in Cardiology
    1996 Duke University, Faculty in Cardiology
    2013 Stanford University, Vice Chair of Clinical Research, Department of Medicine

  • Anurag Mairal

    Anurag Mairal

    Adjunct Professor, Medicine - Cardiovascular Medicine

    Bio Dr. Anurag Mairal is a Consulting Associate Professor of Medicine and the Director, Global Exchange Program at Stanford Byers Center for Biodesign, Stanford University. In these roles, he leads initiatives focused on applying the biodesign process to resource-constrained settings globally. Further, he facilitates opportunities for students, faculty and fellows at Stanford to work on global healthcare needs. He is part of the founding faculty team for BIOE 371, Global Biodesign: Medical Technology in an International Context, a graduate-level course offered to engineering, business, and medical students at Stanford University. He also has additional appointments as an Adjunct Professor at Stanford Graduate School of Business and Faculty Fellow at the Center for Innovation in Global Health. As a Co-Director of the India Biodesign Phase II initiative, he leads the Forum, a platform for supporting India's medtech entrepreneurs. As the Chair of a BME IDEA APAC, a new initiative to bring together medtech innovation programs in Asia Pacific region, he is focused on building a sustainable organization that supports the needs of innovation stakeholders in the region. Earlier, he served as Associate Director for the Stanford-India Biodesign and Singapore-Stanford Biodesign programs. Concurrently, he is a co-founder and Executive Vice President of Orbees Medical, a SF Bay Area-based strategy consulting firm serving global healthcare industry, with a focus on medtech, pharmaceutical, and digital health industry.

    Dr. Mairal has an extensive background in medical technology development and commercialization, collaborating with partners in the U.S., India, China, and other emerging markets to advance product development, manufacturing, and distribution. Recently, he took two years off from Orbees Medical to take a senior leadership role at PATH, a major global health nonprofit based in Seattle. In this role, he oversaw research and development, commercialization, and implementation of technologies in PATH's medical devices, diagnostics, and digital health divisions. Previously, he held several positions at Johnson & Johnson, including Business Development Director and Product Director for structural heart, cardiology, and peripheral vascular products at Cordis. Before joining J&J, he was a Group Leader and a Process Development Manager at Membrane Technology and Research (MTR). At MTR, he was responsible for business development, strategic alliances, and product development in the bioseparations area. An active mentor to entrepreneurs and industry professionals, he serves on the boards of several for-profit and non-profit organizations and is a Charter Member at EPPIC Global Network.

    Dr. Mairal earned a PhD in chemical engineering from the University of Colorado at Boulder and an MBA from the University of California at Berkeley. He also holds an MS in chemical engineering from the Indian Institution of Technology in Mumbai and a BS in chemical engineering from National Institute of Technology, Raipur. Dr. Mairal was a post-doctoral fellow at the University of Twente, Netherlands and at University of Michigan, Ann Arbor. Dr. Mairal has an MBA from the Haas School of Business at University of California, Berkeley. At Haas, he was a founding co-Chairman of the South Asia Business Conference and Chair of the Biotech Panel for the Asia Business Conference. His work has been published in more than 30 publications, and he has been issued seven patents.

  • David J. Maron

    David J. Maron

    Clinical Professor, Medicine - Cardiovascular Medicine

    Current Research and Scholarly Interests Dr. Maron is the Co-Chair and Principal Investigator of the ISCHEMIA Trial. This large, international, NIH-funded study will determine whether an initial invasive strategy of cardiac catheterization and revascularization plus optimal medical therapy will reduce cardiovascular death or MI in patients with at least moderate ischemia compared to an initial conservative strategy of optimal medical therapy alone.

  • Michael V. McConnell, MD, MSEE

    Michael V. McConnell, MD, MSEE

    Clinical Professor, Medicine - Cardiovascular Medicine

    Current Research and Scholarly Interests My imaging research has involved clinical and molecular Imaging of cardiovascular disease, with a focus on coronary and vascular diseases, including atherosclerosis, aortic aneurysms, and vascular inflammation.

    My prevention research has involved innovative technologies to reduce coronary and vascular disease, including early disease detection plus leveraging mobile health to enhance heart-healthy activities in patients and populations.